AVX 012

Drug Profile

AVX 012

Alternative Names: AVX-012

Latest Information Update: 18 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Instituto de Neurociencias de Alicante
  • Developer AVX Pharma
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dry eyes

Most Recent Events

  • 13 Jul 2017 Phase-II clinical trials in Dry eyes in Spain (Ophthalmic)
  • 01 Jul 2016 Avizorex Pharma files an clinical trial application with the Spanish Competent Authority in Spain for Dry eye syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top